References
Meyer, N. & Penn, L.Z. Nat. Rev. Cancer 8, 976–990 (2008).
Dang, C.V. Cell 149, 22–35 (2012).
Zack, T.I. et al. Nat. Genet. 45, 1134–1140 (2013).
Ciriello, G. et al. Nat. Genet. 45, 1127–1133 (2013).
Leiserson, M.D.M. et al. Nat. Genet. 47, 106–114 (2015).
Cancer Genome Atlas Network. Nature 490, 61–70 (2012).
Lawrence, M.S. et al. Nature 499, 214–218 (2013).
Dees, N.D. et al. Genome Res. 22, 1589–1598 (2012).
Ding, L., Wendl, M.C., McMichael, J.F. & Raphael, B.J. Nat. Rev. Genet. 15, 556–570 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Leiserson, M., Vandin, F., Wu, HT. et al. Reply: Co-occurrence of MYC amplification and TP53 mutations in human cancer. Nat Genet 48, 106–108 (2016). https://doi.org/10.1038/ng.3491
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.3491
- Springer Nature America, Inc.
This article is cited by
-
Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer
Breast Cancer Research (2019)